Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
Principal Investigator
Ging-Yuek Robin HsiungOverview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT01760005Status
Closed for RecruitmentStudy Start/End
Apr 22, 2014 to Apr 30, 2020Locations
UBC HospitalName/Title
Michele Assaly, Research Coordinator Phone
604-822-1782Email Address
michele.assaly@vch.caPurpose of Study
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of gantenerumab and solanezumab in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves cognitive outcomes and disease-related biomarkers.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.